Revolution Medicines
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (15)
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Started: 12/15/2025
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Started: 3/9/2026
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Started: 5/6/2025
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Started: 10/16/2024
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Started: 12/30/2021
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Started: 5/24/2024
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Started: 1/30/2026
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Started: 1/18/2024
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Started: 11/14/2023
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Started: 1/8/2026
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Started: 5/31/2022
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Started: 9/7/2023
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Started: 9/19/2022
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Started: 4/7/2021
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Started: 7/2/2019